Table I.

Patient Characteristics

Characteristics	Patients (n=71)
Median age at transplant, years (range)	29 (17-65)
Males (%)	43 (60%)
Response to first-line therapy
Relapse	40 (56%)
Primary refractory	31 (44%)
Risk factors prior to salvage treatment
0	6 (9%)
1	15 (21%)
2	31 (44%)
3	19 (27%)
Response to ICE
CR	14 (20%)
PR	44 (62%)
MR	6 (9%)
POD	7 (10%)
Conditioning regimen
TLI based	26 (37%)
Chemotherapy only	45 (64%)
Tandem transplants
Intended	12
Achieved	7
Auto-Auto	5
Auto-Allo	2
Time to HDT-ASCT failure (median)	5.7 months
Within 6 months (%)	36 (51%)
Within 12 months (%)	56 (79%)
Within 24 months (%)	68 (96%)
Regimens following HDT-ASCT failure
Gemcitabine-based	45
MOPP	28
Radiation	9
Second transplant	24 (5 Autologous, 19 Allogeneic)*
DLI	5**
Disease status
Alive in remission	9 (13%)
Alive with disease	7 (10%)
Deceased	55 (77%)

^*This does not include the seven patients who received second transplants as part of tandem transplants

^**This includes two patients who received DLI following Auto-Allo tandem transplants CR, complete response; PR, partial response; MR, minor response